WO2002034787A1 - Procede d"elaboration d"albumine de serum d"origine humaine comportant une etape de chauffage - Google Patents
Procede d"elaboration d"albumine de serum d"origine humaine comportant une etape de chauffage Download PDFInfo
- Publication number
- WO2002034787A1 WO2002034787A1 PCT/JP2001/009336 JP0109336W WO0234787A1 WO 2002034787 A1 WO2002034787 A1 WO 2002034787A1 JP 0109336 W JP0109336 W JP 0109336W WO 0234787 A1 WO0234787 A1 WO 0234787A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serum albumin
- human serum
- heat treatment
- yeast
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to a method for producing human serum albumin. More specifically, in the process of producing recombinant human serum albumin (hereinafter sometimes referred to as rHSA) obtained by genetic recombination, heating is performed near the isoelectric point of host-derived contaminants (mainly proteins).
- rHSA recombinant human serum albumin
- the present invention relates to a method of producing HSA including a step of treating.
- HSA Human serum albumin
- HSA Human serum albumin
- the purified HSA is used, for example, for the treatment of hypoalbuminemia due to albumin loss such as surgery, hemorrhagic shock or burns or nephrotic syndrome.
- HSA has been obtained from human plasma by low-temperature ethanol fractionation of corn or an HSA fraction (HSA is fractionated into fraction V) according to the method, and then various purification methods are used. It is manufactured.
- human serum albumin has been applied to yeast, Escherichia coli, and Bacillus subtilis by applying genetic recombination technology. Techniques for producing min have been developed.
- Serum Albumin Gene in the Yeast Saccharomyces cerevisiae; Ken.
- purification methods usually used in protein diagnosing for example, salting out method, ultrafiltration method, isoelectric point precipitation method, electrophoresis method, ion exchange chromatography method , Gel filtration chromatography, affinity chromatography and the like can be used.
- protein diagnosing for example, salting out method, ultrafiltration method, isoelectric point precipitation method, electrophoresis method, ion exchange chromatography method , Gel filtration chromatography, affinity chromatography and the like can be used.
- the culture supernatant of the recombinant yeast producing human serum albumin was subjected to ultrafiltration, heat treatment, acid treatment, ultrafiltration again, and then a cation exchanger, 3 ⁇ 47J ⁇
- a method for producing the human serum albumin which comprises subjecting it to each of the following treatments: kutomatto, anion exchanger, and salt prayer.
- This manufacturing method is intended to suppress coloring by performing a heat treatment in the presence of a reducing agent.
- Several other methods for producing human serum albumin including a heat treatment step have been reported, and various effects based on the heat treatment have been recognized. For example, Japanese Patent Publication No. 6-711434 and Japanese Patent Application Laid-Open No.
- 8-116985 disclose the culture supernatant of human serum albumin prepared by genetic manipulation, using acetyltributophan or an organic carboxylic acid. It is described that heating at 50 ° C. to 70 ° C. for 1 to 5 hours in the presence of is inactivating the protease.
- Japanese Patent Application Laid-Open No. 7-126182 describes that contaminating microorganisms are inactivated by heating a recombinant human albumin preparation at 50 to 70 ° C. for 30 minutes or more.
- an object of the present invention is to provide a method for effectively removing contaminants present in human serum albumin.
- Another object of the present invention is to provide human serum albumin which is highly safe as a pharmaceutical.
- the present inventors have made intensive studies in view of the above circumstances, and as a result, have diluted the culture of human serum albumin-producing recombinant yeast, cation-exchanged, monomerized albumin multimer by alkali treatment, and After filtration, the resulting rHSA-containing solution was subjected to a heat treatment at a pH near the isoelectric point of the host-derived protein, thereby finding that the host-derived contaminating protein was effectively removed.
- the present invention has been completed.
- the present invention provides a method for producing human serum albumin, comprising a step of heat-treating a human serum albumin solution containing impurities at a pH near the isoelectric point of the impurities. It provides the law.
- the present invention also includes high-purity rHSA containing no contaminating proteins obtained by the method.
- the present invention will be described in detail.
- FIG. 1 is a drawing showing analysis results of gel filtration HPLC. BEST MODE FOR CARRYING OUT THE INVENTION
- the method of the present invention is characterized in that, in the process of producing human serum albumin, a human serum albumin solution containing host-derived contaminating proteins is heated at a pH near the isoelectric point of host-derived contaminating proteins. is there.
- yeast-derived contaminants can be easily removed, and high-purity human serum albumin can be produced.
- An object to be subjected to the heat treatment of the present invention includes an rHSA-containing solution containing contaminant proteins derived from an rHSA-producing host obtained by a genetic recombination technique.
- Such hosts are not particularly limited, and include yeast, Escherichia coli, Bacillus subtilis, and animal cells.
- yeast for example, Saccharomyces or Pichia is used, and more preferably, Saccharomyces cerevisiae AH22 strain or a mutant thereof is used.
- the method of the present invention can be applied not only to rHSA-producing recombinant hosts but also to cases where protein components derived from plasma are contained as impurities.
- the heat treatment of the present invention can be used at any stage of the rHSA (or plasma-derived human serum albumin) production process.
- the method of the present invention may be carried out using a culture supernatant of a recombinant yeast producing human serum albumin or a crushed yeast solution, a rHSA-containing solution appropriately pretreated with these, or an ion exchanger, adsorption chromatography, or gel filtration. It is desirable to use it at the stage where purification has progressed through processing such as salt prayer.
- the culture supernatant of rHSA-producing yeast was diluted 2- to 3-fold with purified water. Later applied after cation exchanger, alkali treatment and ultrafiltration.
- the cation exchanger treatment is performed according to a usual method.
- the cation exchanger include sulfoagarose, sulfocell mouth, sulfopropyl-agarose, sulfopropyl-dextran, sulfopropyl-polyvinyl, carboxymethyl-agarose, carboxymethyl-dextran, and carboxymethyl-cellulose.
- any carrier may be used.
- a human serum albumin solution adjusted to the same pH is added to a cation exchange column equilibrated with 5 (M-acid buffer (PH4.5)) containing sodium chloride, washed, and washed with 300 mM sodium chloride. Elution with 50m phosphate buffer (pH 9.0) containing danidium to obtain HSA fraction ⁇
- an alkali treatment is performed to monomerize the multimer of human serum albumin generated in the culture or production process.
- an aqueous solution of an alkaline solution having a pH of from 8 to 11, preferably from pH 8.5 to 9.5 is used.
- the temperature for the alkali treatment is not necessarily room temperature, and the treatment can be performed at a temperature at which HSA and rHSA are not denatured, for example, in the range of 0 to 65 ° C.
- the method of leaving at room temperature (about 25 ° C) is adopted.
- Monomerization of a multimer of human serum albumin is performed by mixing an aqueous solution containing the multimer and an alkaline solution, and then allowing the mixture to stand for at least 15 minutes. Preferably, it is 3 hours or more, and the upper limit is not particularly limited.
- the chemical substance used to make the pH of the processing solution of the fermentation viscous is not particularly limited.
- alkaline organic compounds, alkaline inorganic compounds, specifically, ammonia, ammonium salts, basic metal hydroxides (eg, sodium hydroxide, potassium hydroxide), borates, phosphates, acetates examples thereof include substances selected from the group consisting of oxalate, citrate, trishydroxyamino methane, and a mixture of two or more of these.
- Such chemicals are used at concentrations that do not denature human serum albumin.
- the SH group-containing compound used in the treatment is not particularly limited as long as it is a compound containing a functional group SH group, but a low molecular compound having an SH group is preferable.
- Specific examples include cysteine, cysteamine, cisamine, methionine, and the like.
- cysteine is used.
- the amount of the SH group-containing compound to be added is 0.1 to 50 mM, preferably 0.2 to 15 mM, more preferably 0.5 to 5 mM, with respect to the rHSA concentration of 1 to 100 nig / ml.
- the pH is adjusted to near the isoelectric point of the contaminants, and heat treatment is performed.
- the heat treatment is preferably performed at 50 ° C to 70 ° C, more preferably at 55 ° C; to 60 ° C, most preferably at 60 ° C.
- the heating time is preferably 30 minutes to 5 hours, more preferably 1 hour.
- the pH during the heat treatment is preferably around the isoelectric point of the contaminants.
- the pH is preferably 4 to 7, and more preferably Is pH 5-6, most preferably pH 5.5 ⁇
- the concentration of human serum albumin during the heat treatment is not particularly limited as long as the human serum albumin can be dissolved, but is preferably 10 to 250 mg / ml, more preferably 80 to 20 mg / ml. It is.
- the purity of human serum albumin after the heat treatment step can be measured by gel filtration HPLC analysis.
- For the column for example, use TSKgel G300SW (manufactured by Tosoichi). Used, and developed with 0.1MK3 ⁇ 4P0 4 /0.3MNaCl buffer, measuring the absorbance of 2 8 0 nm.
- a non-heat-treated human serum albumin solution obtained by the same method is used.
- yeast According to the method described in Tokuhei 1 1—5 0 9 5 25, yeast (
- Saccharomyces cerevisiae produced rHSA.
- the culture solution containing rHSA was diluted with purified water to about twice the volume, and then adjusted to pH 4.5 with an acetic acid aqueous solution. It was applied to a streamline SP column (manufactured by Amersham Pharmacia Biotech) (diameter: 60 cm ⁇ 16 cm) equilibrated with a 50 mM sodium acetate buffer (pH 4.5) containing 50 mM salted sodium. Next, the column was washed with the same buffer as that used for equilibration of the column. Next, 50 phosphate buffer (PH9.0) containing 300 mM sodium chloride was sent to the column, and rHSA was transferred. The containing fraction was obtained.
- Preparation Example 2 Alcamine treatment of cysteine-containing albumin solution
- the rHSA aqueous solution was concentrated at an rHSA concentration of about 100 mg / m using an ultrafiltration membrane (manufactured by Sartorius) having a molecular weight cut-off of 10,000, and a 50 mM phosphate buffer containing 5 mM sodium caprylate.
- the solution was changed to pH 5.5.
- the rHSA solution was heated at 60 for 1 hour.
- the mixture was cooled to room temperature, the generated precipitate was removed by centrifugation, and the supernatant was recovered.
- Experimental example 1 Gel filtration HPLC analysis
- a human serum albumin non-producing yeast culture was roughly purified in the same manner as in the present invention, and immunized to rabbits.
- an ELISA measurement system was constructed according to a standard method, and the HS obtained in the present invention was obtained. Yeast-derived components present in the A-containing solution were measured. The results are shown in Table 1.
- table 1 A human serum albumin non-producing yeast culture was roughly purified in the same manner as in the present invention, and immunized to rabbits.
- an ELISA measurement system was constructed according to a standard method, and the HS obtained in the present invention was obtained.
- Yeast-derived components present in the A-containing solution were measured. The results are shown in Table 1.
- table 1 A human serum albumin non-producing yeast culture was roughly purified in the same manner as in the present invention, and immunized to rabbits.
- an ELISA measurement system was constructed according to a standard method, and the HS obtained in the present invention was obtained.
- a human serum albumin-containing solution containing host-derived contaminant proteins is subjected to a heat treatment at a pH near the isoelectric point of the contaminants, whereby the contaminant proteins can be easily and effectively removed. Can be removed.
- high-purity human serum albumin having a reduced content of host-derived substances that cause side effects such as allergy when administered to humans.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2395590A CA2395590C (en) | 2000-10-24 | 2001-10-24 | Method of producing human serum albumin involving heating step |
AU10936/02A AU783638B2 (en) | 2000-10-24 | 2001-10-24 | Method of producing human serum albumin involving heating step |
EP01978883A EP1329462B1 (en) | 2000-10-24 | 2001-10-24 | Method of producing human serum albumin involving heating step |
DE60125218T DE60125218T2 (de) | 2000-10-24 | 2001-10-24 | Verfahren zur herstellung von humanen serumalbumin unter einbeziehen eines erwärmungsschrittes |
US10/175,103 US6908749B2 (en) | 2000-10-24 | 2002-06-20 | Method for preparing human serum albumin containing heat-treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-324030 | 2000-10-24 | ||
JP2000324030A JP4798833B2 (ja) | 2000-10-24 | 2000-10-24 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/175,103 Continuation US6908749B2 (en) | 2000-10-24 | 2002-06-20 | Method for preparing human serum albumin containing heat-treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002034787A1 true WO2002034787A1 (fr) | 2002-05-02 |
Family
ID=18801621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/009336 WO2002034787A1 (fr) | 2000-10-24 | 2001-10-24 | Procede d"elaboration d"albumine de serum d"origine humaine comportant une etape de chauffage |
Country Status (12)
Country | Link |
---|---|
US (1) | US6908749B2 (ja) |
EP (1) | EP1329462B1 (ja) |
JP (1) | JP4798833B2 (ja) |
KR (1) | KR100839937B1 (ja) |
CN (1) | CN1313493C (ja) |
AT (1) | ATE348111T1 (ja) |
AU (1) | AU783638B2 (ja) |
CA (1) | CA2395590C (ja) |
DE (1) | DE60125218T2 (ja) |
DK (1) | DK1329462T3 (ja) |
ES (1) | ES2272548T3 (ja) |
WO (1) | WO2002034787A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004083245A2 (en) * | 2003-03-15 | 2004-09-30 | Delta Biotechnology Limited | Agent comprise an albumin-like first polypeptide bound to a second polypeptide |
CN106749623A (zh) * | 2016-12-09 | 2017-05-31 | 浙江大学 | 一种基于混合模式的扩张床吸附分离人血白蛋白方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60121196T2 (de) * | 2000-10-24 | 2007-07-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Verfahren zur monomerisierung von humanen serumalbumin-polymeren |
DE60224284T2 (de) | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
AU2003281982A1 (en) * | 2002-11-26 | 2004-06-18 | Novo Nordisk A/S | Process for purifying a fermentation-derived product |
CN102940879B (zh) | 2003-06-03 | 2017-06-06 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
WO2004105790A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
CN104826116A (zh) | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
DE602005013912D1 (de) | 2004-01-20 | 2009-05-28 | Chemo Sero Therapeut Res Inst | Verfahren zur herstellung von humanserumalbumin durch wärmebehandlung in gegenwart von zweiwertigem kation |
ES2442223T3 (es) | 2004-08-31 | 2014-02-10 | Novo Nordisk A/S | Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas |
CN106137952B (zh) | 2004-11-12 | 2020-11-17 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
JP2009520714A (ja) | 2005-12-22 | 2009-05-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 低オクタノエート型ヒトアルブミン |
JP4936272B2 (ja) * | 2006-02-13 | 2012-05-23 | 独立行政法人科学技術振興機構 | バイオナノカプセルの効率的な精製法 |
WO2009003061A1 (en) | 2007-06-25 | 2008-12-31 | Fred Hutchinson Cancer Research Center | Methods and compositions regarding polychalcogenide compositions |
ES2761854T3 (es) | 2016-10-04 | 2020-05-21 | Albumedix Ltd | Usos de albúmina de suero recombinante obtenida a partir de levadura |
TWI762706B (zh) | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5071897A (ja) * | 1973-11-07 | 1975-06-14 | ||
JPH0317023A (ja) * | 1989-06-15 | 1991-01-25 | Green Cross Corp:The | アルブミン製剤及びその製法 |
EP0570916A2 (en) * | 1992-05-20 | 1993-11-24 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025500A (en) * | 1974-06-06 | 1977-05-24 | Baxter Laboratories, Inc. | Preparation of albumin by fractionation of blood plasma or serum |
IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
US5004688A (en) * | 1988-04-15 | 1991-04-02 | Phillips Petroleum Company | Purification of hepatitis proteins |
JP2926722B2 (ja) | 1988-10-20 | 1999-07-28 | 吉富製薬株式会社 | アルブミン製剤及びその製造方法 |
JPH0671434B2 (ja) * | 1989-09-18 | 1994-09-14 | 株式会社ミドリ十字 | ヒト血清アルブミンの製造方法 |
JPH04234326A (ja) * | 1990-12-27 | 1992-08-24 | Green Cross Corp:The | アルブミン製剤及びその製法 |
JPH0671434A (ja) | 1991-05-30 | 1994-03-15 | Tadahiro Omi | クリーンチャンバーの溶接方法 |
US5521287A (en) * | 1992-05-20 | 1996-05-28 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
JP3269504B2 (ja) * | 1992-07-08 | 2002-03-25 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの製造方法 |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
JPH07126182A (ja) * | 1993-10-27 | 1995-05-16 | Green Cross Corp:The | 組換えヒト血清アルブミン製剤の滅菌方法 |
JP3840674B2 (ja) * | 1994-08-31 | 2006-11-01 | 三菱ウェルファーマ株式会社 | 遺伝子操作に由来するヒト血清アルブミンの精製方法 |
AU3868197A (en) * | 1996-08-23 | 1998-03-06 | Kirin Beer Kabushiki Kaisha | Yeast vectors and process for producing proteins with the use of the same |
JP2885212B2 (ja) * | 1997-01-06 | 1999-04-19 | 吉富製薬株式会社 | 遺伝子操作由来のヒト血清アルブミンより得られる高純度ヒト血清アルブミン含有組成物 |
-
2000
- 2000-10-24 JP JP2000324030A patent/JP4798833B2/ja not_active Expired - Fee Related
-
2001
- 2001-10-24 CA CA2395590A patent/CA2395590C/en not_active Expired - Fee Related
- 2001-10-24 DE DE60125218T patent/DE60125218T2/de not_active Expired - Lifetime
- 2001-10-24 EP EP01978883A patent/EP1329462B1/en not_active Expired - Lifetime
- 2001-10-24 CN CNB018056466A patent/CN1313493C/zh not_active Expired - Fee Related
- 2001-10-24 DK DK01978883T patent/DK1329462T3/da active
- 2001-10-24 AU AU10936/02A patent/AU783638B2/en not_active Ceased
- 2001-10-24 WO PCT/JP2001/009336 patent/WO2002034787A1/ja active IP Right Grant
- 2001-10-24 AT AT01978883T patent/ATE348111T1/de not_active IP Right Cessation
- 2001-10-24 ES ES01978883T patent/ES2272548T3/es not_active Expired - Lifetime
- 2001-10-24 KR KR1020027008242A patent/KR100839937B1/ko active IP Right Grant
-
2002
- 2002-06-20 US US10/175,103 patent/US6908749B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5071897A (ja) * | 1973-11-07 | 1975-06-14 | ||
JPH0317023A (ja) * | 1989-06-15 | 1991-01-25 | Green Cross Corp:The | アルブミン製剤及びその製法 |
EP0570916A2 (en) * | 1992-05-20 | 1993-11-24 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004083245A2 (en) * | 2003-03-15 | 2004-09-30 | Delta Biotechnology Limited | Agent comprise an albumin-like first polypeptide bound to a second polypeptide |
WO2004083245A3 (en) * | 2003-03-15 | 2004-11-04 | Delta Biotechnology Ltd | Agent comprise an albumin-like first polypeptide bound to a second polypeptide |
CN106749623A (zh) * | 2016-12-09 | 2017-05-31 | 浙江大学 | 一种基于混合模式的扩张床吸附分离人血白蛋白方法 |
CN106749623B (zh) * | 2016-12-09 | 2020-04-10 | 浙江大学 | 一种基于混合模式的扩张床吸附分离人血白蛋白方法 |
Also Published As
Publication number | Publication date |
---|---|
AU783638B2 (en) | 2005-11-17 |
CA2395590A1 (en) | 2002-05-02 |
EP1329462A4 (en) | 2004-09-08 |
JP2002128796A (ja) | 2002-05-09 |
CN1406246A (zh) | 2003-03-26 |
EP1329462B1 (en) | 2006-12-13 |
DE60125218D1 (de) | 2007-01-25 |
CA2395590C (en) | 2012-12-11 |
JP4798833B2 (ja) | 2011-10-19 |
US20020182680A1 (en) | 2002-12-05 |
DE60125218T2 (de) | 2007-09-20 |
ATE348111T1 (de) | 2007-01-15 |
AU1093602A (en) | 2002-05-06 |
KR100839937B1 (ko) | 2008-06-20 |
CN1313493C (zh) | 2007-05-02 |
DK1329462T3 (da) | 2007-01-22 |
ES2272548T3 (es) | 2007-05-01 |
KR20020065609A (ko) | 2002-08-13 |
EP1329462A1 (en) | 2003-07-23 |
US6908749B2 (en) | 2005-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4798833B2 (ja) | 加熱処理工程を含むヒト血清アルブミンの製造方法 | |
AU2005205314B2 (en) | Process for producing human serum albumin by heating in presence of divalent cation | |
JP4798832B2 (ja) | ヒト血清アルブミン多量体の除去方法 | |
CA2395587C (en) | Method of monomerizing human serum albumin polymers | |
AU2017232582B2 (en) | Method for producing activated hepatocyte growth factor (HGF) | |
KR102060881B1 (ko) | 재조합 인간 혈청 알부민의 수용성 과발현 및 정제 방법 | |
JP4798831B2 (ja) | ヒト血清アルブミンのミスホールディングを抑制する方法 | |
JP4798830B2 (ja) | ヒト血清アルブミン多量体の単量体化方法 | |
JP2885212B2 (ja) | 遺伝子操作由来のヒト血清アルブミンより得られる高純度ヒト血清アルブミン含有組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10175103 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2395590 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027008242 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001978883 Country of ref document: EP Ref document number: 10936/02 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027008242 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018056466 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2001978883 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 10936/02 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001978883 Country of ref document: EP |